Pfizer has acquired a smaller company for $4.9 billion to enhance its position in the GLP-1 market, aiming to compete with leaders like Eli Lilly and Novo Nordisk. The pharmaceutical giant’s recent investments suggest a push into this lucrative space, potentially driving growth in the future. Pfizer’s improving financials and diverse pipeline make it an attractive investment option.

Read more at Yahoo Finance: Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?